DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Chardan Capital Upgrades Arbutus Biopharma to Buy, Raises Price Target to $5

Chardan Capital analyst Keay Nakae upgrades Arbutus Biopharma (NASDAQ:ABUS) from Neutral to Buy and raises the price target from $1.5 to $5.

Benzinga · 03/06/2020 11:47

Chardan Capital analyst Keay Nakae upgrades Arbutus Biopharma (NASDAQ:ABUS) from Neutral to Buy and raises the price target from $1.5 to $5.